The objective of this study was to assess bioequivalence of a potential generic 1 mg
granisetron tablet formulation compared with Roche Laboratories' 1 mg granisetron tablet,
Kytril, following a single 1 mg dose, under fasting conditions.
- No clinically significant abnormal finding on the physical examination, medical
history, or clinical laboratory results during screening.
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to granisetron or any other comparable or